Literature DB >> 19432889

Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.

Naoko Imai1, Hiroaki Ikeda, Isao Tawara, Linan Wang, Lijie Wang, Hiroyoshi Nishikawa, Takuma Kato, Hiroshi Shiku.   

Abstract

We have reported for the first time the significance of effector T-cell multifunctionality in antitumor immunity, suggesting that the appearance of multifunctional/polyfunctional tumor-specific CD8(+) T cells in vivo is a critical determinant of the success of antitumor immunotherapy, and a strategy to induce multifunctionality in effector cells is required for the successful immunotherapy of hosts with progressing tumor. Glucocorticoid-induced tumor necrosis factor receptor (GITR) stimulation has been shown to enhance antitumor immune response. However, its functional impact on adoptively transferred T cells remains unclear. Here, we analyzed the impact of GITR stimulation in vivo on the functional profiles of adoptively transferred CD8(+) T cells specific for murine fibrosarcoma CMS5. GITR stimulation was found to enhance multifunctionality (interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production and CD107a mobilization as a degranulation marker) in transferred cells at the single-cell level. These cells exhibited upregulated expression of CD25 in draining lymph nodes and increased infiltration in tumor. Mice that received T-cell therapy with GITR stimulation showed reduced Foxp3(+)CD4(+) T cells among tumor infiltrating lymphocytes and increased in vivo cytotoxic T lymphocytes (CTL) activity even with progressing tumor, resulting in enhanced tumor regression. These data strengthen the idea that effector T-cell multifunctionality is a sensitive immune correlate for successful immunotherapy against malignancy and provide an immunological rationale for effective T-cell therapy combined with GITR stimulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432889     DOI: 10.1111/j.1349-7006.2009.01179.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  16 in total

1.  SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Authors:  Abhishek K Srivastava; Gunes Dinc; Rajesh K Sharma; Esma S Yolcu; Hong Zhao; Haval Shirwan
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

Review 2.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

Review 3.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

Review 4.  Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.

Authors:  Iñaki Etxeberria; Irene Olivera; Elixabet Bolaños; Asunta Cirella; Álvaro Teijeira; Pedro Berraondo; Ignacio Melero
Journal:  Cell Mol Immunol       Date:  2020-05-20       Impact factor: 11.530

5.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

6.  Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

Authors:  Smita K Nair; Gabriel De Leon; David Boczkowski; Robert Schmittling; Weihua Xie; Janet Staats; Rebecca Liu; Laura A Johnson; Kent Weinhold; Gary E Archer; John H Sampson; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2014-03-21       Impact factor: 12.531

7.  Th2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo.

Authors:  Nienke van der Werf; Stephen A Redpath; Alexander T Phythian-Adams; Miyuki Azuma; Judith E Allen; Rick M Maizels; Andrew S Macdonald; Matthew D Taylor
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

Review 8.  Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.

Authors:  Theresa Placke; Hans-Georg Kopp; Helmut Rainer Salih
Journal:  Clin Dev Immunol       Date:  2010-09-26

9.  Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

Authors:  Eric Tran; Julie S Nielsen; Darin A Wick; Alvin V Ng; Lisa D S Johnson; Nancy J Nesslinger; Elissa McMurtrie; John R Webb; Brad H Nelson
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

Review 10.  CD8+ T cells: GITR matters.

Authors:  Simona Ronchetti; Giuseppe Nocentini; Maria Grazia Petrillo; Carlo Riccardi
Journal:  ScientificWorldJournal       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.